Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Baxter
Mallinckrodt
Harvard Business School
Boehringer Ingelheim

Last Updated: April 5, 2020

DrugPatentWatch Database Preview

Lupin Atlantis Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for LUPIN ATLANTIS, and what generic alternatives to LUPIN ATLANTIS drugs are available?

LUPIN ATLANTIS has fourteen approved drugs.

There are four US patents protecting LUPIN ATLANTIS drugs. There is one tentative approval on LUPIN ATLANTIS drugs.

There are eighty-five patent family members on LUPIN ATLANTIS drugs in thirty-eight countries and sixteen supplementary protection certificates in nine countries.

Summary for Lupin Atlantis
International Patents:85
US Patents:4
Tradenames:9
Ingredients:8
NDAs:14
Patent Litigation for Lupin Atlantis: See patent lawsuits for Lupin Atlantis

Drugs and US Patents for Lupin Atlantis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Atlantis TRIAMCINOLONE ACETONIDE triamcinolone acetonide CREAM;TOPICAL 208763-001 Feb 1, 2017 AT RX No No   Start Trial   Start Trial
Lupin Atlantis DESOXIMETASONE desoximetasone OINTMENT;TOPICAL 208044-001 Dec 12, 2016 AB RX No No   Start Trial   Start Trial
Lupin Atlantis LEVOTHYROXINE SODIUM levothyroxine sodium TABLET;ORAL 209713-012 Jan 18, 2019 AB1,AB2,AB3 RX No No   Start Trial   Start Trial
Lupin Atlantis LEVOTHYROXINE SODIUM levothyroxine sodium TABLET;ORAL 209713-004 Jan 18, 2019 AB1,AB2,AB3 RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lupin Atlantis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 4,800,079   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 4,800,079   Start Trial
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-002 Nov 30, 2004 4,800,079   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LUPIN ATLANTIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14

Supplementary Protection Certificates for Lupin Atlantis Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0759917 38/2002 Austria   Start Trial PRODUCT NAME: OSELTAMIVIR PHOSPHAT; REGISTRATION NO/DATE: EU/1/02/222/001 EU/1/02/222/002 20020620
1214076 49/2008 Austria   Start Trial PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521 122015000093 Germany   Start Trial PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
0771217 CA 2006 00038 Denmark   Start Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Dow
AstraZeneca
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.